ImmuneOnco won the "Top 20 Innovation and Entrepreneurship in Pudong New Area in 2020"

On the September 29, 2021, Pudong New Area held commendation event for "2021 Outstanding Economic Contribution Enterprises ". ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. won the Price of Top 20 of "2020 Pudong New Area Innovation and Entrepreneursh......

2021-09-29

ImmuneOnco sets up wholly-owned subsidiary—ImmuneOnco BioPharm (Shanghai) Co., Ltd.

On September 28, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") wholly-owned subsidiary-ImmuneOnco BioPharm (Shanghai) Co., Ltd. was established in Zhangjiang Science City (hereinafter ......

2021-09-28

ImmuneOnco Received NMPA Authorization to Proceed with 3 Phase Ib/IIa Clinical Trials of IMM01 Combined with Azacytitin, Rituximab and Inetetamab

August 25, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ( hereinafter referred to as "ImmuneOnco") announced that 3 phase Ib/IIa trials of company’s lead drug candidate, IMM01, Fc fusion protein targeting CD47，the first in China,......

2021-08-26

ImmuneOnco received FDA approval of IMM2902 as an Investigational New Drug (IND) in the United States

August 21, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the U.S. Food and Drug Administration (FDA) has granted permission to IMM2902, a bi-specific antibody-receptor recom......

2021-08-24

ImmuneOnco Succesfully Finished First-in-Human Dosing of Its Bi-Specific Fusion Protein IMM2510

August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been......

2021-08-19